Detalle Publicación


No evidence that CD33 rs12459419 polymorphism predicts gemtuzumab ozogamicin response in consolidation treatment of acute myeloid leukemia patients: experience of the PETHEMA group

Autores: Castaño-Bonilla, T.; Barragán, E.; Sargas, C.; Sanz, A.; Algarra, L.; Herrera-Puente, P.; García-Boyero, R.; Barrios, M.; Martínez-Cuadrón, D.; Rodríguez-Veiga, R.; Boluda, B.; Gil, C.; Serrano-López, J.; Martínez-López, J.; Sayas-Lloris, M. J.; Olave, M. T.; Riaza-Grau, R.; Bernal-Del Castillo, T.; Larráyoz Ilundáin, María José; Amigo, R.; Jiménez-Velasco, A.; Sánchez, J.; Ayala, R.; Blas, C.; Laínez, D.; Serrano-López, J.; Sanz, M. A.; Alonso-Domínguez, J. M. (Autor de correspondencia); Montesinos, P.
Título de la revista: DISEASE MARKERS
ISSN: 0278-0240
Volumen: 2022
Páginas: 3132941
Fecha de publicación: 2022
Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO to intensive treatment in contrast to patients with CT/TT genotypes. Nevertheless, contradictory results have been reported. We sought to shed light on the prediction of GO response in AML patients with rs12459419 polymorphism who were treated with GO in the consolidation (n=70) or reinduction (n=20) phase. The frequency distribution of the rs12459419 polymorphism in the complete cohort of patients was 44.4% (n=40), 50% (n=45), and 5.6% (n=5) for CC, CT, and TT genotypes, respectively. Regarding the patients treated with GO for consolidation, we performed a Kaplan-Meier analysis of overall survival and relapse-free survival according to the rs12459419 polymorphism (CC vs. CT/TT patients) and genetic risk using the European Leukemia Net (ELN) 2010 risk score. We also carried out a Cox regression analysis for the prediction of overall survival, with age and ELN 2010 as covariates. We found no statistical significance in the univariate or multivariate analysis. Additionally, we performed a global Kaplan-Meier analysis for the patients treated with GO for reinduction and did not find significant differences; however, our cohort was too small to draw any conclusion from this analysis. The use of GO in consolidation treatment is included in the approval of the compound; however, evidence regarding its efficacy in this setting is lacking. Rs12459419 polymorphism could help in the selection of patients who might benefit from GO. Regrettably, in our cohort, the rs12459419 polymorphism does not seem to be an adequate tool for the selection of patients who might benefit from the addition of GO in consolidation cycles.